Here’s Why ALS Drug Relyvrio Is Being Removed From Market—And What That Means For Patients

📆 4/4/2024 4:15 PM
📰 ForbesTech

⏱ Reading Time:
20 sec. here
11 min. at publisher
📊 Quality Score:
News: 42%
Publisher: 59%

Amylyx Pharmaceuticals News

Relyvrio,Als,Amyotrophic Lateral Sclerosis

I'm a Texas native covering the latest trends in tech, science and healthcare through explainer pieces on the breaking news team. Previously, I was a Forbes HBCU Scholar writing under the innovation and health and science teams.

Today’s Biden-Netanyahu Call Could Get Tense After WCK Airstrike—But Key Allies Want More Than Tough Talk

$1.2 Billion Powerball Jackpot Is Now The Biggest Of 2024—Here’s What The Winner Could Take Home After TaxesDrug manufacturer Amylyx Pharmaceuticals announced on Thursday plans to remove Relyvrio from the market after lackluster results from a phase III trial, leaving only two other ALS drugs on the market.The process to remove the drug from the market in both Canada and the U.S.

Write Comment

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

Entertainment Entertainment Latest News, Entertainment Entertainment Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Amylyx May Pull FDA-Approved ALS Drug After Failed Phase 3 TrialTopline results for the ALS drug Relyvrio show that it failed to meet primary or secondary endpoints. The company says it may voluntarily pull the drug from the market.
Source: Medscape - 🏆 386. / 55 Read more »